Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...

Last month Arcus reported top -line phase 2 results with the TIGIT drug that it said warranted taking it forward into a phase 3 programme, but so far there's no word from Gilead on a buy-in.

In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – Research ...

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on DTIL stock, giving a Buy rating today.Stay Ahead of the ...

Long term Arcus Biosciences, Inc. (NYSE:RCUS) shareholders know that all too well, since the share price is down considerably over three years. Unfortunately, they have held through a 65% decline ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...

Marcus Freeman has done a tremendous job in Year 3 of his tenure at Notre Dame. The former Ohio State Buckeyes linebacker ...

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Arcus Biosciences has a twelve month low of $13.52 and a twelve month high of $20.31. The firm’s 50 day moving average price is $16.19 and its 200 day moving average price is $16.06.

HAYWARD, Calif., December 19, 2024--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, has been garnering attention from investors and analysts alike due to its ...